ClinicalTrials.gg
RecruitingNCT05195385CASCADEUpdated Mar 30, 2026

Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

An interventional study of Low-dose computed tomography of the chest in Lung Cancer Screening, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,635
Allocation
Not applicable
Ages
50 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 12
2,635 · median 235
Started
2022
the only one that year
No phase
8 of 19
5 open now
Registered
13th of 19
by date

Among the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 8 with no phase, and was the 13th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether reading of low-dose thoracic CT scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts.

The study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.

Read the detailed description

Lung cancer is the leading cause of cancer death, worldwide. Several randomized studies have demonstrated that annual or biennial low-dose CT screening reduces lung cancer mortality. However, these studies involved expert chest radiologists, with double reading being performed in most studies. Furthermore, none of the published studies have evaluated the role of artificial intelligence to serve as second of concurrent reader.

Women with at least 20 pack-year smoking history who quitted smoking less than 15 years ago will be enrolled to have baseline, 1-year and 2-year low-dose CT of the chest.

The CT scans will be read on site by a general radiologist trained to lung cancer screening according to the European lung cancer screening certification program, first without then with the aid of an artificial algorithm trained to lung nodule detection (Veye Chest, Aidence). All CT scans will also be read by 2 chest experts, who will resolve their disagreement by a consensus reading if necessary. Patient management will rely on the double reading by expert. The criteria for positive screen result are as follows: solid nodule > 500 mm3 (10 mm) or growing (30% volume increase), part-solid nodule with > 8 mm solid component or new or growing, pure ground glass nodule developing a solid portion.

03

Conditions studied

  • Lung Cancer Screening

Browse trials for

Keywords

  • lung neoplasms
  • multidetector computed tomography
  • early detection of cancer
  • artificial intelligence
  • lung cancer screening
04

Who can participate

Ages eligible
50 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged from 50 to 74 years
  • who had smoked at least 20 pack years and quit less than 15 years ago
  • Had given their consent and accepted the need for a 2-year follow-up
  • Affiliated to the social security system

Exclusion criteria

Exclusion Criteria

  • Presence of clinical symptoms suggesting (weight loss, hemoptysis) or ongoing infection (cough with fever)
  • Evolving cancer
  • History of lung cancer
  • A 2-year follow-up not possible
  • Chest CT scan performed within 2 years prior to inclusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,635 participants (estimated)

Study arms

  • Other
    Procedure

    Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

    Procedure: Low-dose computed tomography of the chest

Interventions

  • ProcedureLow-dose computed tomography of the chest

    Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

06

What researchers measure

Primary outcomes

  1. Performance of trained radiologists for lung cancer screening

    Sensitivity, specificity, predictive values compared to double reading by experts

    Time frame: 2 years

Secondary outcomes

  1. Effectiveness of screening

    Proportion of participants with a positive screening test and proportion of confirmed diagnosis of cancer

    Time frame: 2 years

  2. Analysis of the diagnostic performance of the reading without detection software, in order to assess its incremental value

    For the general population and for the COPD population. Sensitivity, specificity, predictive values and likelihood ratios of the initial reading compared to the expert readings, using histological diagnosis as gold standard for positive screens and stability at 2 years for negative screens

    Time frame: 2 years

  3. Analysis of the performance of a reading by detection software alone

    For the general population and for the COPD population. Sensitivity, specificity, predictive values and likelihood ratios of artificial intelligence alone

    Time frame: 2 years

  4. Analysis of the concordances of the different readings

    Kappa concordance coefficient between the different readings

    Time frame: 2 years

  5. Adherence to screening

    Number of participants related to the number of eligible women, having completed all the required scans (3 to 6), speed of inclusion in the study. Enrolment will be assessed on the basis of the following characteristics: weaned or non-weaned smokers, level of education, socio-economic category, etc

    Time frame: 2 years

  6. Analysis of the impact of screening on smoking cessation

    Smoking cessation rate at the end of the study

    Time frame: 2 years

  7. Psychological impact of screening

    HADS (Hospital Anxiety and Depression Scale) questionnaire at each scan, Cancer worry scale, Satisfaction with Decision scale at inclusion and end of study, all translated into French

    Time frame: 2 years

  8. Number of co-morbidities (COPD, coronary artery disease) detected

    Number of participants related to the number of women included in the study for whom treatment is initiated (bronchodilators/ statins or revascularization/ osteoporosis treatment)

    Time frame: 2 years

  9. Evaluation of costs induced by screening

    Cost measures: total cost of screening, average cost per woman, average cost per woman screened

    Time frame: 2 years

  10. Prevalence of osteoporosis by opportunistic screening

    Presence of at least one thoracic vertebral fracture and measurement of trabecular attenuation of the T8 vertebral body

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Revel MP, Abdoul H, Chassagnon G, Canniff E, Durand-Zaleski I, Wislez M. Lung CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol. BMJ Open. 2022 Dec 8;12(12):e067263. doi: 10.1136/bmjopen-2022-067263. PubMed 36600392 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Oct 2027, 66 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 66 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2022
First posted
Jan 19, 2022
StartActual
Apr 8, 2022
Primary completionEst.
Oct 8, 2027
CompletionEst.
Oct 8, 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05195385
Collaborators
Ministère de la Santé et des Solidarités, National Cancer Institute, France, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Apr 8, 2022
Primary completion
Oct 8, 2027 (estimated)
Completion
Oct 8, 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Marie-Pierre REVEL, PhD
Contact
marie-pierre.revel@aphp.fr
+33 1 42 34 79 10
Adèle BELLINO, MS
Contact
adele.bellino@aphp.fr
+33 1 58 41 11 95
Marie-Pierre REVEL, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris
Marie WISLEZ, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion